Influence of Craniosacral Therapy on Anxiety, Depression and Quality of Life in Patients with Fibromyalgia
Table 2
Differences in quality of life (SF-36 questionnaire) between study groups.
Baseline M (SD)
P
Pre-T
25 weeks M (SD)
P
1-PT
6 months M (SD))
P
2-PT
1 year M (SD)
P
3-PT
SF-36
IG
PG
IG
PG
IG
PG
IG
PG
PF
49.43 (6.90)
51.90 (9.92)
.199
45.90 (5.87)
50.53 (9.12)
.009*
46.05 (4.61)
49.05 (8.03)
.049*
47.43 (5.32)
50.68 (7.54)
.367
PR
25.17 (6.88)
25.86 (7.35)
.661
22.10 (6.84)
25.80 (6.98)
.019*
23.85 (7.05)
25.47 (7.09)
.067
24.67 (7.24)
26.01 (7.83)
.121
BP
75.76 (7.20)
78.43 (12.75)
.257
73.12 (6.08)
78.00 (13.07)
.036*
74.25 (6.74)
78.65 (13.22)
.052
74.84 (7.04)
77.39 (10.65)
.234
GH
67.02 (4.25)
68.28 (6.84)
.258
64.40 (4.65)
68.35 (6.39)
.048*
66.02 (4.12)
67.92 (6.69)
.087
66.72 (5.21)
67.63 (7.02)
.321
V
60.05 (5.23)
58.90 (6.27)
.376
62.73 (5.27)
59.48 (7.73)
.046*
60.80 (5.11)
58.72 (7.78)
.050*
61.34 (4.96)
59.01 (5.74)
.201
SF
63.23 (7.12)
63.93 (12.41)
.758
58.75 (6.74)
63.50 (11.57)
.028*
59.85 (10.93)
63.05 (11.87)
.075
60.45 (8.67)
64.45 (10.29)
.067
RE
49.18 (7.65)
46.35 (5.69)
.065
45.60 (7.85)
47.23 (5.66)
.292
49.65 (6.52)
46.40 (5.96)
.053
48.33 (8.31)
47.42 (7.29)
.135
MH
76.65 (11.23)
80.60 (9.66)
.097
77.48 (8.73)
81.15 (10.42)
.069
74.15 (12.12)
77.80 (7.84)
.074
75.64 (9.86)
79.45 (10.35)
.083
Values are presented as means and standard deviations (SD). IG, intervention group; PG, placebo group; Pre-T, pre-therapy; 1 PT, post-therapy after 25 weeks of treatment; 2 PT, post-therapy at 6 months after end of treatment; 3 PT, post-therapy at 1 year after end of treatment; PF, physical function; PR, physical role; BP, body pain; GH, general health; V, vitality; SF, social function; ER, emotional role; MH, mental health. *P = .05 (95% CI).
